Table 4.
Studya | Year | Study populationb | n | Treatment condition | Treatment length | OPP typec | OPP (mean) | SD |
---|---|---|---|---|---|---|---|---|
Kolli et al. (present study in controls) | 2021 | CTRL | 121 | Baseline | 1 week | Mean | 46.8 | 8.1 |
Timolol | 48.5 | 7.9 | ||||||
Latanoprost | 49.6 | 8.2 | ||||||
Baseline | Systolic | 108.5 | 14.4 | |||||
Timolol | 106.9 | 13.7 | ||||||
Latanoprost | 110.2 | 13.1 | ||||||
Baseline | Diastolic | 61.3 | 10.8 | |||||
Timolol | 62.0 | 10.8 | ||||||
Latanoprost | 64.7 | 10.0 | ||||||
Seibold et al.24 | 2017 | POAG/OHT | 30 | Baseline | 4 weeks | Mean | 39.5 | 4.9 |
Timolol | 40.7 | 4.4 | ||||||
Lee et al.25 | 2016 | NTG | 44 | Baseline | 4 weeks | Mean | 47.9 | 7.3 |
Latanoprost | 47.5 | 7.2 | ||||||
Baseline | Diastolic | 63.2 | 9.1 | |||||
Latanoprost | 62.8 | 10.1 | ||||||
Liu et al.26 | 2016 | POAG/OHT | 25 | Baseline | 4 weeks | Mean | 52.8 | 8.0 |
Timolol | 54.8 | 7.5 | ||||||
Rossetti et al.27 | 2015 | POAG/OHT | 99 | Baseline | 4 weeks | Diastolic | 62.4 | 11.1 |
Timolol and Latanoprost | 62.8 | 6.9 | ||||||
Baseline | Systolic | 111.8 | 15.3 | |||||
Timolol and Latanoprost | 120.2 | 15.7 | ||||||
Oddone et al.28 | 2015 | POAG/OHT | 32 | Baseline | 8 weeks | Diastolic | 59.8 | 9.1 |
Timolol | 59.5 | 7.7 | ||||||
Baseline | Systolic | 109.2 | 15.7 | |||||
Timolol | 105.2 | 11.4 | ||||||
Quaranta et al.29 | 2012 | POAG/OHT | 28 | Baseline | 8 weeks | Mean | 54.9 | 6.1 |
Timolol | 48.0 | 9.0 | ||||||
Konstas et al.30 | 2009 | POAG/OHT | 29 | Baseline | 8 weeks | Mean | 36.1 | 6.9 |
Timolol | 43.2 | 5.5 | ||||||
Quaranta et al.31 | 2008 | POAG/OHT | 27 | Baseline | 6 weeks | Diastolic | 47.4 | 3.32 |
Latanoprost | 55.9 | 2.48 | ||||||
Koz et al.32 | 2007 | POAG/OHT | 51 | Baseline | 6 months | Mean | 33.5 | 3.2 |
Latanoprost | 39.9 | 3.1 | ||||||
Quaranta et al.33 | 2006 | POAG/OHT | 27 | Baseline | 6 weeks | Diastolic | 50.7 | 5.9 |
Timolol | 53.0 | 5.5 | ||||||
Latanoprost | 56.4 | 4.9 | ||||||
Gherghel et al.34 | 2006 | POAG/OHT | 51 | Baseline | 6 months | Mean | 39.0 | 7.9 |
Latanoprost | 50.4 | 7.5 | ||||||
Fuchsjäger-Mayrl et al.35 | 2005 | POAG/OHT | 70 | Baseline | 6 months | Mean | 39.3 | 7.4 |
Timolol | 41 | 8.3 | ||||||
Inan et al.23 | 2003 | POAG/OHT | 20 | Baseline | 3 months | Mean | 40.7 | 5 |
Latanoprost | 46.6 | 2.9 | ||||||
Harris et al.36 | 2003 | NTG | 20 | Baseline | 4 weeks | Mean | 48 | 9 |
Timolol | 48 | 7 | ||||||
Liu et al.37 | 2002 | NTG | 28 | Baseline | 4 weeks | Mean | 45.7 | 4.3 |
Latanoprost | 49.3 | 5.9 | ||||||
Drance et al.38 | 1998 | NTG | 27 | Baseline | 3 weeks | Mean | 49.5 | 6.7 |
Timolol | 50.9 | 5.7 | ||||||
Latanoprost | 53.2 | 7.3 |
For studies that reported OPP values at multiple times during the day, we present values from the morning measurement in this table.
Study population: CTRL: Healthy volunteers, POAG/OHT, NTG.
Mean OPP = ⅔ [DBP + ⅓ (SBP − DBP)] − IOP. Systolic OPP = (SBP − IOP). Diastolic OPP = (DBP − IOP).
NTG, normal tension glaucoma; POAG/OHT, primary open-angle glaucoma and ocular hypertension.